Dr. Russell H. Ellison

Executive Director, Torreya Partners

New York City

Dr. Ellison currently serves as Executive Director of Torreya Partners - M&A and financial advisory firm where he leads the Strategic Investment group. Russell is also President and CEO of Bond Biosciences Inc, a privately held biotech company focused on the development of non absorbed oral chelators of metals for the treatment of genetic disorders, and as Managing Partner of Alameda Consulting LLC. Dr. Ellison served as the Chairman and Chief Executive Officer at Assembly Biosciences NASDAQ:ASMB (formerly Ventrus Biosciences 2010-2014) a biotech company focused on Hepatitis B and microbiome therapeutics for GI disorders from June 2010 to February 2015 . He served as an Executive Vice President of Paramount BioSciences LLC from 2007 - 2010, and he served as Vice President of Clinical Development at Fibrogen Inc, NASDAQ:FGEN 2005-2007. He served as the U.S. Vice President of Medical Affairs and Chief Medical Officer at Sanofi-Synthelabo, based in the United States, from 2002 - 2006, as the U.S. Vice President of Medical Affairs and the Chief Medical Officer at Hoffmann La Roche US from 1997-2002 and as Vice President at Roche Canada from 1990 to 1997. He has also held senior-level medical affairs and drug development positions at Hoechst Canada, Inc., Glaxo Canada, and Pharma International, Ciba Geigy, based in Basel. He served as an Independent Director of Cougar Biotechnology Inc., previously, and as a Director of ProSanos Corporation. He holds an M.D. from the University of British Columbia and an M.Sc., with distinction, from The London School of Tropical Medicine and Hygiene.